NIKKEI 225
28,567.14 -237.71 (-0.83%) HANG SENG
26,150.24 +23.31 (+0.09%) CRUDE OIL
84.63 +0.87 (+1.04%) GOLD FUTURES
1,799.90 +3.60 (+0.20%) DOW
35,677.02 +73.92 (+0.21%) BTC-GBP
45,027.38 +520.50 (+1.17%)
Cara Therapeutics, Inc. (CARA)
- Simply Wall St.
Are Cara Therapeutics, Inc.'s (NASDAQ:CARA) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?
Cara Therapeutics (NASDAQ:CARA) has had a rough month with its share price down 8.8%. It seems that the market might...
- Motley Fool
Is Cara Therapeutics Stock a Buy After Its First FDA Drug Approval
Cara Therapeutics (NASDAQ: CARA) recently scored a key win with Food and Drug Administration approval of Korsuva in treating pruritis associated with chronic kidney disease for patients on hemodialysis. In this Motley Fool Live video recorded on Aug. 25, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not Cara stock is a buy after the big news. Another biotech had some good news on the FDA front: Cara Therapeutics, ticker there is CARA, and its partner Vifor Pharma (OTC: GNHAY) announced on Monday that the FDA had approved Korsuva for trading moderate to severe pruritus associated with chronic kidney disease, and this is in adults undergoing dialysis.
- Motley Fool
Why Cara Therapeutics Shot Higher Today
Cara Therapeutics (NASDAQ: CARA) was a hot stock on Tuesday. One of the formerly clinical-stage biotech's drug candidates won FDA approval, and investors reacted in the usual manner. The biotech company's most promising drug, Korsuva --- developed with Switzerland-based Vifor Pharma -- addresses this medical challenge sufficiently to win that all-important FDA approval.
